GLP-1s and PCOS hormones: what the evidence actually shows

What did @livferro actually say?

The transcript provided is actually the lyrics to "American Pie" by Don McLean, not a discussion of GLP-1s or PCOS. However, the video caption tells a more specific story: @livferro claims that six months on "peptide management" normalized her testosterone levels, which she describes as significant for her PCOS. She calls the changes "life changing" and frames the hormonal shift as more meaningful than the visible physical transformation.

That's worth taking seriously as a claim, even if the audio didn't deliver the science lesson the caption promised. The caption is making a hormonal efficacy claim tied to GLP-1 receptor agonists, and that claim deserves scrutiny on its own merits.

Does the science back this up?

More than you might expect, actually. The link between GLP-1 receptor agonists and improved androgen profiles in PCOS patients is one of the more interesting findings in recent metabolic research. A 2023 meta-analysis by Xie et al. in Frontiers in Endocrinology found that GLP-1 RA treatment in women with PCOS was associated with statistically significant reductions in free androgen index and total testosterone. The mechanisms aren't fully pinned down, but weight loss itself drives down androgen levels partly by reducing insulin resistance, and GLP-1s are potent insulin sensitizers on top of whatever direct ovarian effects may be in play.

A 2022 study by Jensterle et al. in Obesity Reviews compared semaglutide to lifestyle intervention in PCOS patients and found greater hormonal improvements in the semaglutide group independent of the amount of weight lost. That's a meaningful distinction. It suggests this isn't purely a "lose weight, fix hormones" story.

What did they get wrong (or right)?

The caption gets the broad strokes right. Testosterone normalization after GLP-1 treatment in PCOS is a real, documented phenomenon. Credit where it's due. The framing is also appropriately personal: she's reporting her own labs, not telling other PCOS patients what will happen to them.

What's hazier is the phrase "peptide management." This is a catch-all term that blurs important distinctions. GLP-1 receptor agonists like semaglutide are not interchangeable with other peptides circulating in wellness spaces. Compounded semaglutide is not the same product as FDA-approved Wegovy or Ozempic. If she's on a compounded formulation, that context matters for how others interpret her results. The caption doesn't draw that line.

Also worth noting: six months is a short window. Whether those testosterone improvements hold at 12 or 24 months, particularly if weight is regained after stopping treatment, is an open question the research hasn't fully answered yet.

What should you actually know?

PCOS affects roughly 8-13% of reproductive-age women globally, according to the WHO, and hyperandrogenism, elevated testosterone being the most common marker, is a core feature of the condition. Standard care has historically leaned on oral contraceptives and metformin. GLP-1 receptor agonists represent a genuinely different mechanism, and the early data on their hormonal effects in PCOS is promising enough that several endocrinology groups are actively revising clinical guidance.

That said, no GLP-1 drug is currently FDA-approved specifically for PCOS. Prescribing for PCOS-related androgen excess is off-label. Anyone considering this path should be working with a clinician who can actually measure their baseline hormones and track changes, not just going by how they feel. Lab-confirmed testosterone levels, as @livferro says she tracked, is the right approach. Anecdote plus bloodwork is more useful than anecdote alone.

• GLP-1s appear to lower androgens in PCOS patients through both weight-dependent and potentially weight-independent pathways.
• Compounded peptides and brand-name GLP-1 drugs are not equivalent products.
• Off-label use requires proper clinical supervision and monitoring.